DOR by azole subgroup in patients with GVHD. Patients with SR-aGVHD (A) and patients with SR-cGVHD (B) treated with ruxolitinib (RUX) or BAT, with or without azoles. Data reported for full analysis set. bid, twice daily; N/A, not available; NE, not evaluable.